[gate width=”400px”][maxbutton id=”1″ url=”http://clpmag.com/wp-content/uploads/clpmag/2017/04/HCV_ProductBulletinVF.pdf” ][/gate]
Prior to 2011, therapies for the treatment of hepatitis C focused on interferon-based therapy. In 2011 it was found that the genotype of the hepatitis C virus (HCV) is clinically important for determining a patient’s response to both interferon-based therapy and other potential therapies. Current guidelines from the American Association for the Study of Liver Diseases recommend specific combination therapies for each HCV genotype as well as subtypes 1a and 1b1.
Among patients with HCV genotype 1, the introduction of such targeted therapies has reduced adverse effects and increased cure rates from 45% to 93%. Further research to develop additional genotype-specific targeted therapies will continue to improve outcomes for this disease. This research makes accurate determination of HCV genotype critical for the development of novel therapies for hepatitis C.
Download the white paper to read more.
